A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

NCT02372227 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
21
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Verastem, Inc.